The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Next-generation diagnostic and prognostic approaches in multiple myeloma
Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, discusses next-generation diagnostic and prognostic approaches in multiple myeloma (MM). He highlights advanced tools for stratifying patient risk, including combined diagnostic and measurable residual disease (MRD) dynamic risk models and the International Staging System (ISS). Dr Paiva notes the dynamic nature of risk and the variety of treatments available, such as anti-CD38 antibodies, proteasome inhibitors, and transplantation. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
